Showing results (411-420 of 458) with videos related to
Sort By:
Pageof 46
Clinical Genitourinary Cancer|November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaNeeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.The New England Journal of Medicine|February 18, 2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R Smith, Maha Hussain, Fred Saad, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group studyEmeline Colomba, Gwénaël Le Teuff, Tim Eisen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.The Lancet. Oncology|March 15, 2021
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, et al.Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.Pageof 46